Short Course Radiation Therapy in Palliative Treatment of Esophageal Cancer

Esophageal Cancer Clinical Trial

Official title:

SHort Course Accelerated RadiatiON Therapy (SHARON) in Palliative Treatment of Esophageal Cancer: an Interventional, Randomized, Multicentric Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03804203
• Other study ID #: RT 15-07 SHARON ESOPHAGUS
• Status: Recruiting
• Phase: N/A
• Start date: November 8, 2017
• Est. completion date: November 8, 2023

Study information

• Verified date: January 2019
• Source: Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
• Contact: Alessio G Morganti, MD
• Phone: 0512143564
• Email: alessio.morganti2[@]unibo.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic esophageal malignant lesions

Description:

Standard treatment for esophageal lesions (3000 cGy in 10 daily fractions of 300 cGy each) is compared with experimental treatment (2000 cGy in 4 fractions of 500 cGy twice a day) to demonstrate non-inferiority of this scheme

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 98
• Est. completion date: November 8, 2023
• Est. primary completion date: November 8, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• symptomatic esophageal malignant lesions (primary solid tumors or metastases from solid tumor);

• age>18 years;

• ECOG performance status 0-3

• no changes in supportive care in the week before radiotherapy

Exclusion Criteria:

• pregnancy

• previous irradiation of the same region

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms
• Palliative Care
• Radiotherapy

Intervention

Radiation:
• standard treatment
3000 cGy in 10 daily fractions
• short course treatment
2000 cGy in 4 fractions administered twice a day

Locations

Country	Name	City	State
Italy	Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine- DIMES, University of Bologna, S.Orsola-Malpighi Hospital	Bologna	BO

Sponsors (1)

Lead Sponsor	Collaborator
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of palliation using the short course scheme compared with the standard scheme: Likert scale	reduction of initial symptoms after radiotherapy, assessed with Likert scale (dysphagia, odynophagia, regurgitation, chest-back pain are evaluated as none-mild-moderate-severe)	3 months
Secondary	acute toxicity in the two treatment groups	incidence of treatment-related acute adverse events in the two arms of the study registered using Cooperative Group Common Toxicity Criteria	3 months
Secondary	late toxicity in the two treatment groups	incidence of treatment-related adverse events in the two arms of the study registered using RTOG/EORTC Late Radiation Morbility Scoring Schema	12 months
Secondary	Quality of Life (QoL): EORTC questionnaire C15-PAL	changes in QoL after the treatment assessed using European Organization for Research and Treatment of Cancer (EORTC) questionnaire C15-PAL (a specific questionnaire from EORTC developed to assess the quality of life of palliative cancer care patients)	12 months